Ipilimumab (anti-CTLA-4)

Ask supplier a question | View on supplier's website

Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD.

Supplier	Selleck Chemicals
Product #	A2001
Sku #	A2001-1mg
Pricing	1mg, $667.00

Citations for this product:

Therapy-induced senescence upregulates antigen presentation machinery and triggers anti-tumor immunity in Acute Myeloid Leukemia

Diego Gilioli, et al., bioRxiv - Cancer Biology 2022

Quote: ... at the start of the co-culture cells were treated with 10 μg/mL Ipilimumab (anti-CTLA-4, cat#A2001 from Selleck Chemicals), Nivolumab (anti-PD-1 ...

Feedback